Literature DB >> 16451254

Progression of visual field loss in open angle glaucoma in the Melbourne Visual Impairment Project.

Mimiwati Zahari1, Bickol N Mukesh, Julian L Rait, Hugh R Taylor, Catherine A McCarty.   

Abstract

PURPOSE: To quantify the progression of visual field loss in participants with open angle glaucoma.
METHODS: Cluster random samples of 3271 participants participated in this study. Each participant underwent a standardized ophthalmic examination, which included intraocular pressure measurement, Humphrey 24-2 Fastpac visual field testing and stereophotography of the optic disc. At baseline 118 participants were identified as possible, probable or definite open angle glaucoma and 74 (62.7%) of these were seen again at the follow-up examination. Progression of visual field loss was defined using three methods: the Advanced Glaucoma Intervention Study criteria, the modified Anderson criteria and the Blumenthal method.
RESULTS: In total, 49% of subjects showed progressive visual field loss with at least one method. The Blumenthal criteria yielded the highest rate of progression (37%), followed by the modified Anderson method (33%) and the Advanced Glaucoma Intervention Study method (16%). The progressive visual field loss was associated with baseline glaucoma status (P = 0.02); 65% of the definite glaucoma progressed, compared with 57% of the probable glaucoma and 25% of the possible glaucoma. Participants who had been previously diagnosed with glaucoma had a higher rate of progression (54%) when compared with those who had not been diagnosed previously (47%). In total, 50% (four of eight) of those receiving glaucoma medication at baseline had progressive visual field loss; all were in the definite glaucoma category.
CONCLUSION: Despite use of glaucoma medications the majority of glaucoma patients managed by their regular ophthalmologist experienced progressive visual field loss over a 5-year period.

Entities:  

Mesh:

Year:  2006        PMID: 16451254     DOI: 10.1111/j.1442-9071.2006.01142.x

Source DB:  PubMed          Journal:  Clin Exp Ophthalmol        ISSN: 1442-6404            Impact factor:   4.207


  6 in total

1.  Visual field progression in Malay patients with primary glaucoma: survival analysis and prognostic factors.

Authors:  Wan Masri Wan-Ezatul-Arisha; Shi Jin Diana-Toh; Abdul Satar Huwaina; Majdi Yaakob Najib; Yaakub Azhany; Bachok Norsa'adah; Ahmad Tajudin Liza-Sharmini
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2021-11-01       Impact factor: 3.117

2.  Risk factors and long term progression in open angle glaucoma patients.

Authors:  Anca Delia Pantalon; Crenguţa Feraru; Dorin Chiseliţă
Journal:  Rom J Ophthalmol       Date:  2016 Jul-Sep

Review 3.  Practical recommendations for measuring rates of visual field change in glaucoma.

Authors:  B C Chauhan; D F Garway-Heath; F J Goñi; L Rossetti; B Bengtsson; A C Viswanathan; A Heijl
Journal:  Br J Ophthalmol       Date:  2008-01-22       Impact factor: 4.638

4.  Filtering data from the collaborative initial glaucoma treatment study for improved identification of glaucoma progression.

Authors:  Greggory J Schell; Mariel S Lavieri; Joshua D Stein; David C Musch
Journal:  BMC Med Inform Decis Mak       Date:  2013-12-21       Impact factor: 2.796

5.  Rates of visual field progression in clinical glaucoma care.

Authors:  Anders Heijl; Patricia Buchholz; Gunilla Norrgren; Boel Bengtsson
Journal:  Acta Ophthalmol       Date:  2012-10-16       Impact factor: 3.761

6.  Rationale and protocol for the 7- and 8-year longitudinal assessments of eye health in a cohort of young adults in the Raine Study.

Authors:  Samantha Sze-Yee Lee; Gareth Lingham; Seyhan Yazar; Paul G Sanfilippo; Jason Charng; Fred K Chen; Alex W Hewitt; Fletcher Ng; Christopher Hammond; Leon M Straker; Peter R Eastwood; Stuart MacGregor; Kathryn A Rose; Robyn M Lucas; Jeremy A Guggenheim; Seang-Mei Saw; Minas T Coroneo; Mingguang He; David A Mackey
Journal:  BMJ Open       Date:  2020-03-25       Impact factor: 2.692

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.